Companies: 10,795·Total market cap: $144.5T
Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.

SYRENASDAQHealthcare● Active
$71.96
$-1.69(-2.29%)
Market Cap$4.3B
P/E Ratio
52W High$78.8
52W Low$13.93
Overview

Spyre Therapeutics, Inc. (SYRE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · SYRE · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.18syre eps ttm · syre earnings per shareEarnings history
PE Ratio (TTM)syre pe ratio ttm · syre price to earningsPE Ratio deep dive
Revenue (TTM)$90.5Msyre revenue ttm · syre annual revenueFull revenue history
Dividend YieldNo Dividenddoes syre pay dividends · syre dividend yieldDividend history
Shares Outstanding346.0Msyre shares outstanding · syre floatShares outstanding history
Next EarningsAug 4, 2026Est.syre earnings date · syre next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
spyre therapeutics, inc. revenue · syre revenue 2025
FY 2025Net Income-$155.2M▲ +25.39% YoY
202320242025
spyre therapeutics, inc. net income · syre profit 2025
FY 2025EPS$-1.98▲ +37.74% YoY
202320242025
syre eps · spyre therapeutics, inc. earnings per share 2025
TTM:Revenue: $90.5MNet Income: -$179.4MEPS: $-2.18View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy11 analystsis syre a buy · syre analyst rating
Strong Buy
0
Buy
11
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$49.00Low
$71.96Current
$86.64Avg Target20.40% upside
$115.00High
syre price target · syre 12 month forecast

Total: 11 · Buy rate: 100.0%

The SYRE analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $86.64, representing +20.40% upside from the current price of $71.96.

Stock Performance

Full History
1D-2.86%
1W+1.72%
1M-4.68%
3M+78.18%
YTD+118.38%
1Y+316.90%
5Y-57.92%

About Spyre Therapeutics, Inc.

CEOCameron Turtle
IPO DateApr 7, 2016
Employees73
CountryUS
Websitespyre.com

Spyre Therapeutics, Inc. a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclona…

what is spyre therapeutics, inc. · syre stock overview · spyre therapeutics, inc. company profile · who is spyre therapeutics, inc. ceo · syre NASDAQ · spyre therapeutics, inc. headquarters · spyre therapeutics, inc. business segments

About Stock Overview & Key Data

Spyre Therapeutics, Inc. (SYRE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 7, 2016. As of the latest trading session, SYRE stock price is $71.96, with a market capitalization of $4.3B. The stock has returned +316.90% over the past 12 months and +118.38% year-to-date.

According to 11 Wall Street analysts, the consensus rating for Spyre Therapeutics, Inc. stock is Buy, with an average 12-month price target of $86.64. In fiscal year 2025, Spyre Therapeutics, Inc. reported revenue of — and net income of -$155.2M. For detailed data — including Spyre Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Spyre Therapeutics, Inc. (SYRE) stock price is $71.96. The stock is traded on NASDAQ under the ticker symbol SYRE. The 52-week range is $13.93 – $78.80.

SYRE stock priceSYRE quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice